Vaccine to prevent liver cancer return after surgery
Part of Cancer clinical trials.
This trial tests a personalized vaccine plus a booster (IL-12) to see if it can stop liver cancer from coming back after surgery. It compares the vaccine to just watching and waiting.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have been diagnosed with liver cancer (HCC) that was removed by surgery
- You have a tumor tissue sample available from your surgery
- Your liver function is good (Child-Pugh Class A)
- You are able to do your daily activities with little or no help (ECOG 0 or 1)
- You do not have active autoimmune disease, HIV, or certain hepatitis coinfections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a treatment given before surgery for liver cancer that is at high risk of coming back. You would receive a combination of chemotherapy directly into the liver artery (HAIC), a targeted pill (lenvatinib), and an immunotherapy drug (a PD-1 inhibitor) — if a computer model predicts you might benefit.
This trial tests a tailored treatment plan after surgery for liver cancer that shows a specific blood vessel pattern (VETC). The goal is to find the best follow-up therapy to lower the chance of cancer coming back.
This trial is testing a new treatment made from your own immune cells (called CT011 CAR-T cells) to see if it can lower the risk of liver cancer coming back after surgery. It is designed for people with advanced liver cancer that has spread into nearby blood vessels.
This trial tests whether giving an immunotherapy drug (anti-PD-1) after surgery can help prevent liver cancer from coming back. It is for people who have had their liver tumor completely removed and have good enough liver function.
This trial tests a personalized mRNA vaccine (iNeo-Vac-R01) combined with a PD-1 inhibitor to prevent liver cancer from coming back after surgery. It is for people with early-stage liver cancer who have a high risk of recurrence.
This trial tests a new drug that combines two immunotherapy approaches (PD-1 and IL-2) given before surgery to treat hepatocellular carcinoma (liver cancer) that has come back 3 months to 2 years after your first surgery. The goal is to shrink the tumor and help your body's immune system fight the cancer.
Hear when a new HCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.